Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Miraculins closes $400,000 private placement:

This article was originally published in Clinica

Executive Summary

Canadian cancer biomarker specialist Miraculins has raised $428,000 from the private placement of approximately 1.2 million units of company stock at a price of $0.35 per unit. Each unit comprised of one common share and half a share purchase warrant. One whole warrant enables the holder to purchase a Miraculins share at $0.65 per share for the twelve-month period after the issuing of the unit. Winnipeg, Manitoba-based Miraculins said the proceeds would be used for R&D and working capital purposes. The company's main focus is on biomarker discovery using its BEST Platform, for screening and identifying target proteins and peptides related to diseases.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049701

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel